Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5601–5650 of 75391
Douglas D. Wheat, the Chairman of the Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (the “Company”) notified the Company and the Board that he will not stand for re-election at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”), at which time he will retire from the Board.
Mr. Rush served as President & Chief Executive Officer since November 2022 and is retiring after 25 years of dedicated service to the Company, effective November 6, 2024.
On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.
announced the planned transition and departure of John P. Zimmer as the Company’s Executive Vice President, Secretary, Treasurer and Chief Financial Officer, which departure will be effective as of May 31, 2025
On November 8, 2024, Kenneth J. Fasola, President of Centene Corporation (the "Company"), informed the Company that he intends to retire from the Company on July 1, 2025.
On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).
Additionally, on November 8, 2024, Chang Yee Lee submitted a letter of resignation as a member of the Board.
On November 8, 2024, Dr Hj Mazlan Hj Ahmad submitted a letter of resignation as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of QMIS TBS Capital Group Corp., a Delaware corporation (the “Company”), effective immediately.
On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024.
On November 5, 2024, Jeff Desroches resigned as Executive Vice President, Chief Operations Officer of BJ’s Wholesale Club Holdings, Inc. (the “Company”) effective as of such date.
On November 11, 2024, Robert J. Ott, the Senior Vice President and Corporate Controller for TE Connectivity plc (the “Company”), announced his intent to retire effective January 3, 2025.
Andrew Davis notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Business Officer, effective November 22, 2024.
On November 7, 2024, Phibro Animal Health Corporation (the “Company”) was notified by Rob Aukerman that he will be retiring from his position as President, North America Region of the Company effective December 31, 2024.
As a result of his illness, Mr. Wert was removed from the board of directors on October 25, 2024.
due to the illness of the Chief Executive Officer, Charles Wert
On November 8, 2024, iSpecimen Inc. (the “Company”) and Tracy Curley mutually agreed to end Ms. Curley’s employment as Chief Executive Officer, Chief Financial Officer and Treasurer of the Company.
Ms. Curley resigned as a member of the Board of Directors (the “Board”), due to differences between Ms. Curley and the Board regarding the future direction of the Company.
On November 7, 2024, Joseph E. Sutaris notified Community Financial System, Inc. (the “Company”) of his intention to retire, effective in or around the third quarter of 2025, from his position as the Executive Vice President (“EVP”) and Chief Financial Officer of the Company
Mr. Campbell is no longer a Principal of the Campbell Fund Trust and has retired as Chairman of the Board of Campbell & Company’s general partner.
Xiao Xing has provided notice to the Board of Directors (the “Board”) of ACM Research, Inc. (the “Company”) that she will resign as a member of the Board and the Audit Committee, effective November 15, 2024.
the resignation of Mr. William H. Craig as Chief Financial Officer and Treasurer of the Company
Robert A. Fehlman (age 60), the chief executive officer of Simmons First National Corporation (“Company”), provided the Company notice of his decision to resign from his position, effective as of the end of the day December 31, 2024, to focus on personal interests and family medical issues.
On November 12, 2024, Science Applications International Corporation (the “Company”) announced that Michelle A. O’Hara, Executive Vice President, Chief Human Resources Officer of the Company, provided her resignation from all positions with the Company effective as of December 6, 2024.
Resignation of Officers Effective as of the consummation of the Transaction, R. Scott Spielvogel and Tony W. Lee resigned their positions as President and as Secretary and Treasurer, respectively, of the Company.
Resignation of Officers Effective as of the consummation of the Transaction, R. Scott Spielvogel and Tony W. Lee resigned their positions as President and as Secretary and Treasurer, respectively, of the Company.
Resignation of Director Immediately prior to the consummation of the Transaction, the resignation of R. Scott Spielvogel from the Board went into effect, and Mr. Spielvogel will not serve as a member of the Board following the consummation of the Transaction.
As previously reported, Martha A. Wiegand, General Counsel and Secretary of CONSOL Energy Inc. (the “Company”), departed the Company on August 7, 2024
On November 12, 2024, William Lyon, a member of the Board of Directors (the “Board”) of Taylor Morrison Home Corporation (the “Company”), notified the Company of his decision to retire from the Board, effective November 30, 2024.
On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.
On November 8, 2024, Daniel Marcus, Brian Shwieger and Nicholas Gregory resigned from the Board of Directors of the Company, effective immediately
On November 8, 2024, Daniel Marcus, Brian Shwieger and Nicholas Gregory resigned from the Board of Directors of the Company, effective immediately
On November 8, 2024, Daniel Marcus, Brian Shwieger and Nicholas Gregory resigned from the Board of Directors of the Company, effective immediately
On November 11, 2024, Pacific Biosciences of California, Inc. (the “Company”) notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024.
On November 11, 2024, Healthcare Realty Trust Incorporated (the "Company") and Todd J. Meredith determined that Mr. Meredith would depart from his position as President and Chief Executive Officer of the Company, effective November 11, 2024.
will retire from his employment with the Company, effective January 6, 2025, and from the Board, effective April 30, 2025
Jon Kessler, President & Chief Executive Officer of the Company and a member of the Board of Directors (the “Board”), will retire from his employment with the Company, effective January 6, 2025
Herman Cueto, who is departing from his role at the Company.
Mr. Dellal will resign from his role as of the Effective Date.
On November 7, 2024, Clifton J. Porter II notified the Board of Directors of Sabra Health Care REIT, Inc. (the “Company”) of his decision not to stand for reelection to the Company’s Board of Directors at the Company’s 2025 annual meeting of shareholders.
Mr. Kevin Zaccardi resigned as the Interim-Chief Financial Officer of Starco Brands, Inc. (the “Company”), effective November 8, 2024, to pursue another opportunity.
The Board has received the resignation of James A. Schoonover as a director from the Board which took effect on the Effective Date.
On November 1, 2024, Marqeta announced that Randy Kern was no longer the Chief Product and Technology Officer of the Company, effective immediately (the “Initial Transition Date”).
On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity.
On November 8, 2024 (the “Effective Date”), Laura Janney resigned from her position as the Chief Merchandising Officer of Tilly’s, Inc. (the “Company”) to pursue other interests.
On October 8, 2024, the Board of Directors of the Company terminated Daniel Watson’s employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024 (the "Termination Date").
On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.
On November 6, 2024, Matthew P. Sheehy, a director of the Company, notified the Company of his decision to resign from the Board of Directors of the Company (the “Board”) and all committees of the Board, effective immediately.
On November 11 , 2023, James F. Gero, a director of Intrusion Inc. (the “Company), notified the Board of Directors (the “Board) of his decision to resign from the Board effective November 20, 2024.
On November 7, 2024, Peter Staple notified the Board of Directors (the “Board”) of the Company of his intent to retire as a member of the Board, effective November 7, 2024
On November 7, 2024, Jeffrey Vacirca also notified the Board of the Company of his intent to retire as a member of the Board and its committees, effective as of the Effective Date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.